Johnson & Johnson (NYSE:JNJ) Stock Holdings Lifted by Meadow Creek Wealth Advisors LLC

Meadow Creek Wealth Advisors LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 8.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,535 shares of the company’s stock after buying an additional 536 shares during the period. Johnson & Johnson comprises about 1.4% of Meadow Creek Wealth Advisors LLC’s holdings, making the stock its 7th largest position. Meadow Creek Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,160,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Family CFO Inc purchased a new position in Johnson & Johnson in the fourth quarter worth $26,000. RE Dickinson Investment Advisors LLC boosted its position in Johnson & Johnson by 163.3% in the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC boosted its position in Johnson & Johnson by 200.0% in the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after purchasing an additional 120 shares during the last quarter. Professional Financial Advisors LLC boosted its position in Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after purchasing an additional 68 shares during the last quarter. Finally, Joseph P. Lucia & Associates LLC purchased a new position in Johnson & Johnson in the first quarter worth $38,000. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on JNJ shares. Morgan Stanley cut their price objective on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Monday, September 12th. Wells Fargo & Company upped their price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. UBS Group dropped their price target on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Citigroup dropped their price target on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Finally, SVB Leerink dropped their price target on Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $189.78.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $166.18 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The firm has a market cap of $436.92 billion, a price-to-earnings ratio of 24.19, a PEG ratio of 2.95 and a beta of 0.61. The business’s fifty day moving average is $168.06 and its 200 day moving average is $174.12.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same period in the previous year, the company posted $2.48 EPS. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 10.7 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were paid a $1.13 dividend. The ex-dividend date was Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.72%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Johnson & Johnson declared that its Board of Directors has authorized a share repurchase program on Wednesday, September 14th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 1.2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.